Clinical Trial

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) vaccine in infants with the first dose administered at 6 months of age (MOA) or 6 weeks of age (WOA).
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-21
Trial Details
NCT Number NCT07286370
Lead Sponsor GlaxoSmithKline
Conditions Salmonella Infections
Enrollment 537 participants
Start Date 2026-04-01
Primary Completion 2028-04-27 (estimated)
Study Completion 2028-04-27 (estimated)
Updated on ClinicalTrials.gov 2026-04-20